Celltrion/Teva’s Herceptin biosimilar approved in USThe FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor Share XCelltrion/Teva’s Herceptin biosimilar approved in UShttps://pharmaphorum.com/news/celltrion-tevas-herceptin-biosimilar-approved-in-us/
J&J hits back over asbestos in talc claimsShares in Johnson & Johnson slid around 10% on Friday after a Reuters article claimed the company had Share XJ&J hits back over asbestos in talc claimshttps://pharmaphorum.com/news/jj-hits-back-over-asbestos-in-talc-claims/
Astellas gains three cancer drugs with $405m Potenza buyAstellas has taken an option to acquire US biotech Potenza Therapeutics after the companies spent more than three Share XAstellas gains three cancer drugs with $405m Potenza buyhttps://pharmaphorum.com/news/astellas-gains-three-cancer-drugs-with-405m-potenza-buy/
Ipsen warns over medicine supplies amid Brexit uncertaintyFrance’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma Share XIpsen warns over medicine supplies amid Brexit uncertaintyhttps://pharmaphorum.com/news/ipsen-warns-over-medicine-supplies-amid-brexit-uncertainty/
AZ begins liver cancer immunotherapy tie-up with AVEOAstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in Share XAZ begins liver cancer immunotherapy tie-up with AVEOhttps://pharmaphorum.com/news/az-begins-liver-cancer-immunotherapy-tie-up-with-aveo/
Certain brain tumours could respond to immunotherapySome brain tumours may respond to immunotherapy after all, according to a new study. So far, brain tumours Share XCertain brain tumours could respond to immunotherapyhttps://pharmaphorum.com/news/certain-brain-tumours-could-respond-to-immunotherapy/
Gilead hires Roche’s pharma chief Daniel O’Day as CEORoche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO Share XGilead hires Roche’s pharma chief Daniel O’Day as CEOhttps://pharmaphorum.com/news/gilead-hires-roches-pharma-chief-daniel-oday-as-ceo/
NICE gives final seal of approval for Gilead’s CAR-T in NHLNICE has finalised its guidance recommending interim NHS funding for Gilead’s Yescarta CAR-T therapy, to treat patients with Share XNICE gives final seal of approval for Gilead’s CAR-T in NHLhttps://pharmaphorum.com/news/nice-gives-final-seal-of-approval-for-gileads-car-t-in-nhl/
AZ’s cancer drug fails again, Roche’s rival gets new useAstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved Share XAZ’s cancer drug fails again, Roche’s rival gets new usehttps://pharmaphorum.com/news/azs-cancer-imfinzi-fail/
